-+ 0.00%
-+ 0.00%
-+ 0.00%

ORIC®Pharmaceuticals Initiates Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat In Combination With NUBEQA

Benzinga·07/14/2026 20:07:37
Listen to the news

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone

Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1